Protagonist Therapeutics (PTGX) FDA announcement summary

Introduction and purpose

• ICOTYDE (icotrokinra) received US FDA approval for moderate-to-severe plaque psoriasis in adults and adolescents 12+ weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

• ICOTYDE is the first and only oral peptide-targeted therapy blocking the IL-23 pathway by targeting the IL-23 receptor, offering a novel mechanism compared to injectable antibodies.

• The approval marks a significant milestone after 13 years of R&D and validates the peptide technology platform.

Details of approval or decision

• FDA approval was based on four phase III studies involving about 2,500 patients, all meeting primary endpoints and demonstrating a favorable safety profile.

• The label is broad, covering adults and adolescents, and includes head-to-head superiority data versus Sotyktu and comparisons with other therapies.

• The approval triggers a $50 million milestone payment, with up to $580 million in future milestones and 6–10% royalties, and initiates a royalty-based revenue stream.

• FDA approval was granted in March 2026 for ICOTYDE, formerly known as PN-235.

• ICOTYDE offers the convenience of a once-daily oral pill with efficacy comparable to injectable biologics.

Impact on industry and stakeholders

• ICOTYDE is positioned as a first-in-class, best-in-class oral IL-23R antagonist, potentially transforming the plaque psoriasis treatment landscape and expanding the market by attracting patients who avoid injectables.

• The partnership with Johnson & Johnson includes significant milestone and royalty payments, with J&J responsible for commercialization and ongoing trials.

• Patent protection extends to around 2040, supporting long-term commercial potential.

• Ongoing studies may expand ICOTYDE’s use to psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

• The approval supports a multi-year product-driven growth cycle and pipeline investment.